Amyotrophic Lateral Sclerosis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Amyotrophic Lateral Sclerosis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Corcept Therapeutics, AL-S Pharma, Woolsey Pharmaceuticals, ,Amylyx Pharmaceuticals Inc. Ionis Pharmaceuticals, Inc., Zydus Lifesciences Limited, Helixmith Co., Ltd., Annexon, Inc., Amylyx Pharmaceuticals Inc., Sangamo Therapeutics, PTC Therapeutics, Ferrer Internacional S.A., Rapa Therapeutics LLC, Helixmith Co., Ltd., GlaxoSmithKline, Mallinckrodt, Novartis, Biogen, Sanofi.

[Nevada, United States] - DelveInsight's "Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Amyotrophic Lateral Sclerosis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Amyotrophic Lateral Sclerosis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Amyotrophic Lateral Sclerosis Market Report:
The Amyotrophic Lateral Sclerosis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In October, 2024: PTC Therapeutics announced that their study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
In October, 2024: Corestemchemon, Inc. announced that ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.
In September, 2024: Ionis Pharmaceuticals, Inc. announced that the purpose of their study is to evaluate the efficacy of ION363 on clinical function and survival in carriers fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
In September, 2024: Ferrer Internacional S.A. announced that a Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
In September, 2024: Rapa Therapeutics LLC announced that RAPA-501-ALS is an Intermediate-Size Expanded Access Trial of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
The total prevalent cases of ALS in the 7MM comprised nearly 67,000 in 2023 which are estimated to increase by 2034.
In the US, there were nearly 24,000 diagnosed prevalent cases of ALS in 2023.
Among the type-specific cases, nearly 21,850 cases comprised of sporadic, and 2,430 cases comprised of familial in 2023 in the US.
Among the gender-specific cases, nearly 14,200 cases comprised of males, and nearly 10,000 cases comprised of females in the US in 2023.
Key Amyotrophic Lateral Sclerosis Companies are as follows: Corcept Therapeutics, AL-S Pharma, Woolsey Pharmaceuticals, ,Amylyx Pharmaceuticals Inc. Ionis Pharmaceuticals, Inc., Zydus Lifesciences Limited, Helixmith Co., Ltd., Annexon, Inc., Amylyx Pharmaceuticals Inc., Sangamo Therapeutics, PTC Therapeutics, Ferrer Internacional S.A., Rapa Therapeutics LLC, Helixmith Co., Ltd., GlaxoSmithKline, Mallinckrodt, Novartis, Biogen, Sanofi.
Key Amyotrophic Lateral Sclerosis Therapies are as follow: Masitinib, NurOwn (MSC-NTF cells), QALSODY (tofersen), RADICAVA/RADICUT and RADICAVA ORS, RELYVRIO, EXSERVAN, RILUTEK, NUEDEXTA, ABBV-CLS-7262, RAPA 501, AIT-101, ION541, Dazucorilant, 3K3A-APC, Fasudil, ION363, ANX005, SB-509, AMT-162
Launching multiple stage Amyotrophic Lateral Sclerosis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Amyotrophic Lateral Sclerosis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Amyotrophic Lateral Sclerosis Overview:
ALS, often referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder affecting the nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately respiratory failure. While the exact cause remains unclear, a combination of genetic and environmental factors likely contributes to its onset.

Amyotrophic Lateral Sclerosis Epidemiology Segmentation:
The Amyotrophic Lateral Sclerosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Amyotrophic Lateral Sclerosis Total Prevalent Cases
Amyotrophic Lateral Sclerosis Age-Specific Distribution
Amyotrophic Lateral Sclerosis Gender-specific Distribution
Amyotrophic Lateral Sclerosis Mutation-Specific Distribution
Amyotrophic Lateral Sclerosis Type-Specific Distribution

For more information about Amyotrophic Lateral Sclerosis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Amyotrophic Lateral Sclerosis Market Insights
Currently, there is no cure for ALS and no effective treatment to halt or reverse, the progression ofthe disease. The treatment landscape of ALS includes multidisciplinary care, such asphysicaltherapy, speech therapy, dietary counselling, heat or whirlpool therapy and others
Medications are also prescribed to help manage symptoms of ALS,including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar affect(involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays).

Amyotrophic Lateral Sclerosis Drugs Uptake
Currently, the drugs used for the treatment of ALS include RILTUTEK, EXSERVAN (Riluzole Oral film) and TIGLUTEK (Oral Suspension), RADICAVA (IV and ORS), and QALSODY.
Symptomatic treatments approved are NEUDEXTA, TIGLUTEK, RILUTEK, and others such as anti-epileptic drugs, opioids, NSAIDs, diuretics, SSRIs, antidepressants, etc. for the treatment of ALS.
After the approval of RADICAVA ORS, there was a notable increase in sales for RADICAVA, which had previously been declining for IV RADICAVA.
RELYVRIO gained rapid acceptance in the US market from2022 to 2023. However, following recently presented results from the PHOENIX trial, which did not meet the pre-specified primary or secondary endpoints, as promised, AmylyxPharmaceuticals announced the removal RELYVRIO from the market.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Amyotrophic Lateral Sclerosis Therapies and Key Companies:
Masitinib: AB Science
NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
QALSODY (tofersen): (Biogen/Ionis Pharmaceuticals)
RADICAVA/RADICUT and RADICAVA ORS: Mitsubishi Tanabe Pharma Corporation
RELYVRIO: Amylyx Pharmaceuticals
EXSERVAN: Otsuka Pharmaceutical (Avanir Pharmaceuticals
RILUTEK: Sanofi
NUEDEXTA: Avanir Pharmaceuticals
ABBV-CLS-7262: AbbVie
RAPA 501: Rapa Therapeutics
AIT-101: AI Therapeutics
ION541: Biogen

Amyotrophic Lateral Sclerosis Epidemiology:
ALS is considered a rare disease, but it occurs worldwide and affects individuals across different demographics. Its precise cause remains largely unknown, though it is believed to result from a combination of genetic and environmental factors. The global incidence of ALS is estimated to range between 1.5 and 2.7 cases per 100,000 individuals annually. The prevalence varies from 4 to 10 cases per 100,000 people, depending on geographic region. Higher prevalence rates have been observed in European and North American populations compared to those in Asia and Africa.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Amyotrophic Lateral Sclerosis Market Drivers:
Unmet Medical Need and Demand for Effective Therapies
Advancements in Gene Therapy and Targeted Treatments
Growing R&D Investment and Pipeline Expansion
Regulatory Incentives for Orphan Drug Development

Amyotrophic Lateral Sclerosis Market Barriers:
Complex and Heterogeneous Disease Mechanisms
Limited Biomarkers and Diagnostic Tools
High Costs of Drug Development
Clinical Trial Recruitment and Design Challenges

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Amyotrophic Lateral Sclerosis Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Amyotrophic Lateral Sclerosis Companies: Corcept Therapeutics, AL-S Pharma, Woolsey Pharmaceuticals ,Amylyx Pharmaceuticals Inc. Ionis Pharmaceuticals, Inc., Zydus Lifesciences Limited, Helixmith Co., Ltd., Annexon, Inc., Amylyx Pharmaceuticals Inc., Sangamo Therapeutics, PTC Therapeutics, Ferrer Internacional S.A., Rapa Therapeutics LLC, Helixmith Co., Ltd., GlaxoSmithKline, Mallinckrodt, Novartis, Biogen, Sanofi.
Key Amyotrophic Lateral Sclerosis Therapies: Masitinib, NurOwn (MSC-NTF cells), QALSODY (tofersen), RADICAVA/RADICUT and RADICAVA ORS, RELYVRIO, EXSERVAN, RILUTEK, NUEDEXTA, ABBV-CLS-7262, RAPA 501, AIT-101, ION541, Dazucorilant, 3K3A-APC, Fasudil, ION363, ANX005, SB-509, AMT-162
Amyotrophic Lateral Sclerosis Therapeutic Assessment: Current marketed and emerging therapies
Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis Market drivers and Amyotrophic Lateral Sclerosis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Amyotrophic Lateral Sclerosis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Amyotrophic Lateral Sclerosis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. ALS MARKET OVERVIEW AT A GLANCE
4. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
5. EXECUTIVE SUMMARY
6. KEY EVENTS
7. DISEASE BACKGROUND AND OVERVIEW
8. TREATMENT AND MANAGEMENT OF ALS
9. EPIDEMIOLOGY AND PATIENT POPULATION OF THE 7MM
10. PATIENT JOURNEY
11. KEY ENDPOINTS IN ALS
12. MARKETED DRUGS
13. EMERGING DRUGS
14. ALS: 7MM ANALYSIS
15. UNMET NEEDS
16. SWOT ANALYSIS
17. KOL VIEWS
18. MARKET ACCESS AND REIMBURSEMENT
19. APPENDIX
20. DELVEINSIGHT CAPABILITIES
21. DISCLAIMER
22. ABOUT DELVEINSIGHT

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.